These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37310127)

  • 1. Novel SARS-CoV-2 entry inhibitors, 2-anilinoquinazolin-4(3H)-one derivatives, show potency as SARS-CoV-2 antivirals in a human ACE2 transgenic mouse model.
    Ko M; Lee JY; Shin YS; Jeon S; Myung S; Cho JE; Jang MS; Song JH; Kim HR; Park HG; Park CM; Kim S
    J Med Virol; 2023 Jun; 95(6):e28863. PubMed ID: 37310127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
    Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
    J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
    Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
    J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
    Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
    mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection.
    Sohn SY; Hearing J; Mugavero J; Kirillov V; Gorbunova E; Helminiak L; Mishra S; Mackow E; Hearing P; Reich NC; Kim HK
    mBio; 2021 Dec; 12(6):e0275621. PubMed ID: 34724828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model.
    Cáceres CJ; Cardenas-Garcia S; Carnaccini S; Seibert B; Rajao DS; Wang J; Perez DR
    Sci Rep; 2021 May; 11(1):9609. PubMed ID: 33953295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
    Muturi E; Hong W; Li J; Yang W; He J; Wei H; Yang H
    Int J Antimicrob Agents; 2022 Jan; 59(1):106499. PubMed ID: 34929295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.
    Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice.
    Silvas JA; Vasquez DM; Park JG; Chiem K; Allué-Guardia A; Garcia-Vilanova A; Platt RN; Miorin L; Kehrer T; Cupic A; Gonzalez-Reiche AS; Bakel HV; García-Sastre A; Anderson T; Torrelles JB; Ye C; Martinez-Sobrido L
    J Virol; 2021 Aug; 95(17):e0040221. PubMed ID: 34133899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments.
    Lee JY; Shin YS; Jeon S; Lee SI; Noh S; Cho JE; Jang MS; Kim S; Song JH; Kim HR; Park CM
    Bioorg Med Chem Lett; 2021 May; 39():127885. PubMed ID: 33662537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring SARS-CoV-2 Infection Using a Double Reporter-Expressing Virus.
    Chiem K; Park JG; Morales Vasquez D; Plemper RK; Torrelles JB; Kobie JJ; Walter MR; Ye C; Martinez-Sobrido L
    Microbiol Spectr; 2022 Oct; 10(5):e0237922. PubMed ID: 35980204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits.
    Kim SH; Kim J; Jang JY; Noh H; Park J; Jeong H; Jeon D; Uhm C; Oh H; Cho K; Jeon Y; On D; Yoon S; Lim SY; Kim SP; Lee YW; Jang HJ; Park IH; Oh J; Seo JS; Kim JJ; Seok SH; Lee YJ; Hong SM; An SH; Kim SY; Kim YB; Hwang JY; Lee HJ; Kim HB; Choi KS; Park JW; Seo JY; Yun JW; Shin JS; Lee HY; Kim K; Lee D; Lee H; Nam KT; Seong JK
    Front Immunol; 2022; 13():1055811. PubMed ID: 36457995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and Characterization of a SARS-CoV-2-Susceptible Mouse Model Using Adeno-Associated Virus (AAV6.2FF)-Mediated Respiratory Delivery of the Human ACE2 Gene.
    Tailor N; Warner BM; Griffin BD; Tierney K; Moffat E; Frost K; Vendramelli R; Leung A; Willman M; Thomas SP; Pei Y; Booth SA; Embury-Hyatt C; Wootton SK; Kobasa D
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mild and Severe SARS-CoV-2 Infection Induces Respiratory and Intestinal Microbiome Changes in the K18-hACE2 Transgenic Mouse Model.
    Seibert B; Cáceres CJ; Cardenas-Garcia S; Carnaccini S; Geiger G; Rajao DS; Ottesen E; Perez DR
    Microbiol Spectr; 2021 Sep; 9(1):e0053621. PubMed ID: 34378965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling SARS-CoV-2 Infection in Mice Using Lentiviral hACE2 Vectors Infers Two Modes of Immune Responses to SARS-CoV-2 Infection.
    Katzman C; Israely T; Melamed S; Politi B; Sittner A; Yahalom-Ronen Y; Weiss S; Abu Rass R; Zamostiano R; Bacharach E; Ehrlich M; Paran N; Nissim L
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Generation of SARS-CoV-2 Mouse Model by Transient Expression of the Human ACE2 Gene Mediated by Intranasal Administration of AAV-hACE2].
    Glazkova DV; Bogoslovskaya EV; Urusov FA; Kartashova NP; Glubokova EA; Gracheva AV; Faizuloev EB; Trunova GV; Khokhlova VA; Bezborodova OA; Pankratov AA; Leneva IA; Shipulin GA
    Mol Biol (Mosk); 2022; 56(5):774-782. PubMed ID: 36165016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K18- and CAG-hACE2 Transgenic Mouse Models and SARS-CoV-2: Implications for Neurodegeneration Research.
    Dedoni S; Avdoshina V; Camoglio C; Siddi C; Fratta W; Scherma M; Fadda P
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.